Goat Polyclonal ITM2B antibody. Suitable for IHC-P, WB and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Synthetic Peptide within Human ITM2B aa 200-250.
pH: 7.3
Preservative: 0.02% Sodium azide
Constituents: 99% Tris buffered saline, 0.5% BSA
IHC-P | WB | |
---|---|---|
Human | Tested | Tested |
Mouse | Predicted | Predicted |
Rat | Predicted | Predicted |
Cow | Predicted | Predicted |
Dog | Predicted | Predicted |
Rabbit | Predicted | Predicted |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 2.50000-3.75000 µg/mL | Notes Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Rabbit, Cow, Dog | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1.00000-3.00000 µg/mL | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Rabbit, Cow, Dog | Dilution info - | Notes - |
Select an associated product type
Plays a regulatory role in the processing of the amyloid-beta A4 precursor protein (APP) and acts as an inhibitor of the amyloid-beta peptide aggregation and fibrils deposition. Plays a role in the induction of neurite outgrowth. Functions as a protease inhibitor by blocking access of secretases to APP cleavage sites. Mature BRI2 (mBRI2) functions as a modulator of the amyloid-beta A4 precursor protein (APP) processing leading to a strong reduction in the secretion of secretase-processed amyloid-beta protein 40 and amyloid-beta protein 42. Bri23 peptide prevents aggregation of APP amyloid-beta protein 42 into toxic oligomers.
BRI, BRI2, ITM2B, Integral membrane protein 2B, Immature BRI2, Protein E25B, Transmembrane protein BRI, imBRI2, Bri
Goat Polyclonal ITM2B antibody. Suitable for IHC-P, WB and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Synthetic Peptide within Human ITM2B aa 200-250.
pH: 7.3
Preservative: 0.02% Sodium azide
Constituents: 99% Tris buffered saline, 0.5% BSA
ITM2B also known as Integral Membrane Protein 2B or BRI2 is a transmembrane protein weighing approximately 30 kDa. This protein is expressed widely in human tissues showing particularly high levels in the central nervous system and brain. ITM2B functions mechanically by playing a role in protein processing and trafficking owing to its transmembrane nature. With an integral role in cellular functions ITM2B interacts with various cellular components associated with membrane-related activities.
ITM2B engages in several vital cellular processes such as regulation of amyloid precursor protein (APP) processing. ITM2B forms part of a complex with other proteins involved in APP cleavage which is significant for maintaining cell homeostasis. It also influences neuronal functions through its effects on synaptic plasticity and could impact cognitive abilities. The protein's presence in brain regions ties ITM2B closely to neural activities where protein interactions are essential for cellular communication.
ITM2B exerts influence on critical processes in amyloidogenic pathways contributing to the modulation of amyloid-beta production. This protein directly interacts with other players like APP and presenilin 1 within this pathway affecting the levels of amyloids and ultimately impacting neural integrity. Additionally ITM2B participates in Wnt signaling pathways linking it to cellular differentiation and proliferation where it modulates interactions with proteins that convey Wnt signals such as beta-catenin.
ITM2B is directly linked to familial British dementia and familial Danish dementia both neurodegenerative conditions. These diseases involve mutations in the ITM2B gene leading to abnormal protein aggregates that disrupt normal brain function. ITM2B's relationship with amyloid-beta and presenilin 1 also connects it to Alzheimer's disease pathogenesis where these proteins play roles in amyloid plaque formation a hallmark of Alzheimer's. Studies focus on targeting ITM2B interactions and processing to develop therapies for these conditions highlighting its potential as a therapeutic target.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
All lanes: Western blot - Anti-ITM2B antibody (ab129282) at 1 µg/mL
All lanes: Human Hippocampus lysate (in RIPA buffer) at 35 µg
Developed using the ECL technique.
Predicted band size: 30 kDa
ab129282, at 3.75 µg/ml, staining ITM2B in Formalin-fixed, Paraffin-embedded Human Small Intestine (Myenteric Plexus) tissue by Immunohistochemistry.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com